In MASLD patients, both plasma and hepatic BAs concentrations are increased [73,74], while both FXR and TGR5 pathways are downregulated, as demonstrated in animal and human studies [65,70,75,76]. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.